Livoletide
Livoletide is a synthetic peptide drug that is being investigated for the treatment of Prader-Willi syndrome (PWS), a genetic disorder characterized by insatiable hunger, obesity, and various cognitive and behavioral challenges. Livoletide is designed to mimic the action of the hormone ghrelin, specifically targeting the ghrelin receptor to modulate appetite and food intake.
Mechanism of Action[edit | edit source]
Livoletide acts as an antagonist to the ghrelin receptor, also known as the growth hormone secretagogue receptor (GHS-R). Ghrelin is a hormone that stimulates appetite and is often referred to as the "hunger hormone." In individuals with Prader-Willi syndrome, ghrelin levels are typically elevated, contributing to the hyperphagia (excessive eating) observed in these patients. By blocking the ghrelin receptor, livoletide aims to reduce hunger and food intake, thereby helping to manage weight and improve quality of life in PWS patients.
Clinical Development[edit | edit source]
Livoletide is currently undergoing clinical trials to assess its safety and efficacy in treating hyperphagia associated with Prader-Willi syndrome. Early-phase trials have shown promise, with reductions in hunger scores and food-related behaviors in patients receiving the drug. Ongoing studies aim to further evaluate the long-term benefits and potential side effects of livoletide treatment.
Potential Benefits[edit | edit source]
The primary benefit of livoletide is its potential to reduce hyperphagia in individuals with Prader-Willi syndrome, which could lead to better weight management and a reduction in obesity-related complications. Additionally, by addressing one of the core symptoms of PWS, livoletide may improve overall quality of life and reduce the burden on caregivers.
Side Effects and Considerations[edit | edit source]
As with any investigational drug, the safety profile of livoletide is still being established. Common side effects observed in clinical trials include mild gastrointestinal symptoms, such as nausea and diarrhea. Long-term safety data are still being collected, and patients receiving livoletide should be monitored for any adverse effects.
Regulatory Status[edit | edit source]
Livoletide is not yet approved for general use and is currently available only through clinical trials. The drug's development is being closely monitored by regulatory agencies, and its approval will depend on the outcomes of ongoing studies.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD